Open your account
Empower yourself with cutting-edge tools, expert insights, and unrivaled features.
Announcements
KIMS Q1FY27 Results: Revenue Up 35.3%, Target Price Rs 890
Krishna Institute of Medical Sciences Ltd (KIMS) reported a robust Q1FY27 performance, with revenue surging 35.3% YoY to Rs 1,180 Cr, driven by strong inpatient and outpatient volume expansion. While net profit took a near-term hit due to new hospital incubation costs and finance expenses, the company's long-term profitability looks highly promising. Aggressive debt reduction following a successful Rs 1,500 Cr QIP, rapid operational breakevens at new facilities like Mahadevapura, and a strategic shift toward asset-light expansion models highlight a strong growth trajectory. Analysts maintain a positive outlook, upgrading the target price to Rs 890 per share with a "BUY" rating.
.png&w=3840&q=75)
Other Articles
Prestige Estates Q1FY27 Results: Solid Launch Pipeline Promises Strong Rebound
Prestige Estates Projects Ltd reported a revenue increase of 16% YoY to Rs 2,675 Cr in Q1FY27. Despite a temporarily slow quarter caused by regulatory approval delays, management remains highly confident in achieving a 15-20% pre-sales growth target for the year. With a robust upcoming launch pipeline across key metro cities and an expanding commercial portfolio, Prestige is locking in its long-term expansion strategy!
Prestige Estates Q1FY27 Results: Solid Launch Pipeline Promises Strong Rebound
Prestige Estates Projects Ltd reported a revenue increase of 16% YoY to Rs 2,675 Cr in Q1FY27. Despite a temporarily slow quarter caused by regulatory approval delays, management remains highly confident in achieving a 15-20% pre-sales growth target for the year. With a robust upcoming launch pipeline across key metro cities and an expanding commercial portfolio, Prestige is locking in its long-term expansion strategy!